SIG-003 / Eli Lilly - LARVOL DELTA

Sigilon Therapeutics’ Afibromer Sig-003 for long-term treatement of hemophilia B advances in EU (Hemophilia News Today) - "Sigilon Therapeutics’s Afibromer SIG-003 candidate for the long-term treatment of patients with hemophilia B recently received an Advanced Therapy Medicinal Product (ATMP) designation in the European Union."

Clinical • Genetic Disorders • Hemophilia

Sigilon, MIT collaborating to develop programmable cell therapies for hemophilia, other diseases (Hemophilia News Today) - "Sigilon Therapeutics and the Massachusetts Institute of Technology will work together to develop programmable cell therapeutics for the treatment of hemophilia, lysosomal storage diseases, and other serious chronic illnesses....Alliance with MIT will provide Sigilon access to best-in-class methods for in vivo delivery of therapeutic proteins..."

Licensing / partnership